Systemic Therapy for Hereditary Breast Cancers

被引：2

作者：

Harvey-Jones, Elizabeth J. ^{[1
]}

Lord, Christopher J. ^{[2
,3
]}

Tutt, Andrew N. J. ^{[1
,2
,4
]}

机构：

[1] Breast Canc Now Res Unit, Guys Hosp Canc Ctr, London SE19RT, England

[2] Kings Coll London, City London Canc Res UK Ctr, London SE19RT, England

[3] CRUK Gene Funct Lab, Inst Canc Res, London SW36JB, England

[4] Breast Canc Now Toby Robins Breast Canc Res Ctr, Inst Canc Res, London SW36JB, England

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期

关键词：

Hereditary breast cancer; Chemotherapy; PARPi; Drug resistance; Biomarkers; STANDARD NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; CELL-FREE DNA; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; ADJUVANT CAPECITABINE; INHIBITOR RESISTANCE; REVERSION MUTATIONS; GERMLINE MUTATIONS;

D O I：

10.1016/j.hoc.2022.08.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment options for patients with hereditary breast cancers have expanded significantly in the past 20 years. These include a new FDA-licensed approach to adjuvant therapy, olaparib, that improves OS in those with gBRCA1/2m. However, resistance to platinum-based chemotherapy and PARPi in this cohort of patients is an issue that requires considerable focus. We have discussed standard approaches to treatment, but have touched on the expanse of pre-clinical and early clinical work being undertaken which will likely shape future treatments in this field of medicine.

引用

页码：203 / 224

页数：22

共 50 条

[21] Classification of hereditary breast cancers based on gene expression
Hedenfalk I.
Chen Y.
Duggan D.
Borg Å.
Trent J.
Nature Genetics, 2001, 27 (Suppl 4) : 58 - 58
[22] Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers
McAlarnen, Lindsey
Stearns, Kristen
Uyar, Denise
APPLICATION OF CLINICAL GENETICS, 2021, 14 : 1 - 9
[23] Systemic therapy for biliary tract cancers
Hezel, Aram F.
Zhu, Andrew X.
ONCOLOGIST, 2008, 13 (04): : 415 - 423
[24] Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion
Cagnacci, Angelo
Villa, Paola
Grassi, Giuseppina Paola
Biglia, Nicoletta
Gambacciani, Marco
Di Carlo, Costantino
Nocera, Francesca
Caruso, Salvatore
Becorpi, Angelamaria
Lello, Stefano
Paoletti, Anna Maria
CLIMACTERIC, 2025, 28 (01) : 4 - 14
[25] Systemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion
Cagnacci, Angelo
Villa, Paola
Grassi, Giuseppina Paola
Biglia, Nicoletta
Gambacciani, Marco
Di Carlo, Costantino
Nocera, Francesca
Caruso, Salvatore
Becorpi, Angelamaria
Lello, Stefano
Paoletti, Anna Maria
CLIMACTERIC, 2024,
[26] Hereditary predisposition to breast and other cancers: Medical novelties in 2022
Choismier, Margaux Clement -Le
Kasper, Edwige
Houdayer, Claude
Tennevet, Isabelle
Thery, Jean-Christophe
Parodi, Nathalie
Branchaud, Maud
Callonnec-L'Henaff, Francoise
IMAGERIE DE LA FEMME, 2024, 34 (01) : 1 - 9
[27] Current status of prophylactic surgery for hereditary breast and gynecologic cancers
Lynch, HT
Casey, MJ
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2001, 13 (01) : 25 - 30
[28] Familial or sporadic?: Unexpected results in the diagnosis of hereditary breast cancers
Schiffer, C
Voigtländer, T
Klaes, R
EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 95 - 95
[29] Identification and management of hereditary breast/ovarian cancers (2004 update)
Eisinger, F
Bressac, B
Castaigne, D
Cottu, PH
Lansac, J
Lefranc, JP
Lesur, A
Nogués, C
Pierret, J
Puy-Pernias, S
Sobol, H
Tardivon, A
Tristant, H
Villet, R
BULLETIN DU CANCER, 2004, 91 (03) : 219 - 237
[30] A new paradigm of genetic testing for hereditary breast/ovarian cancers
Kwong, Ave
Chen, J. W.
Shin, Vivian Y.
HONG KONG MEDICAL JOURNAL, 2016, 22 (02) : 171 - 177

← 1 2 3 4 5 →